Production (Stage)
CNS Pharmaceuticals, Inc.
CNSP
$0.811
$0.00370.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -35.67% | 22.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.55% | -43.15% | |||
| Operating Income | -35.55% | 43.15% | |||
| Income Before Tax | -35.41% | 43.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.41% | 43.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.41% | 43.34% | |||
| EBIT | -35.55% | 43.15% | |||
| EBITDA | -35.56% | 43.16% | |||
| EPS Basic | 46.66% | 76.60% | |||
| Normalized Basic EPS | 46.66% | 76.60% | |||
| EPS Diluted | 46.68% | 76.55% | |||
| Normalized Diluted EPS | 46.66% | 76.60% | |||
| Average Basic Shares Outstanding | 153.85% | 142.13% | |||
| Average Diluted Shares Outstanding | 153.85% | 142.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||